Q&A John Maher

John Maher

Q&A John Maher

Comprehensive Cancer Centre

Research output: Other contribution

Abstract

John Maher has worked on CAR T cell immunotherapy with a primary focus on solid tumors for over 20 years. In this Q&A, Cell Reports Medicine interviewed him about his journey in this arena and next steps.

Original language	English
Type	Q&A
Media of output	Cell Reports Medicine
Publisher	CELL PRESS
Number of pages	2
Volume	3
Publication status	Published - 19 Apr 2022

Access to Document

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(22)00112-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2666379122001124%3Fshowall%3DtrueLicence: CC BY

Cite this

@misc{fa7c718f63264d72b29fd42b55309863,

title = "Q&A John Maher",

abstract = "John Maher has worked on CAR T cell immunotherapy with a primary focus on solid tumors for over 20 years. In this Q&A, Cell Reports Medicine interviewed him about his journey in this arena and next steps.",

author = "John Maher",

year = "2022",

month = apr,

day = "19",

language = "English",

volume = "3",

publisher = "CELL PRESS",

type = "Other",

}

TY - GEN

T1 - Q&A John Maher

AU - Maher, John

PY - 2022/4/19

Y1 - 2022/4/19

N2 - John Maher has worked on CAR T cell immunotherapy with a primary focus on solid tumors for over 20 years. In this Q&A, Cell Reports Medicine interviewed him about his journey in this arena and next steps.

AB - John Maher has worked on CAR T cell immunotherapy with a primary focus on solid tumors for over 20 years. In this Q&A, Cell Reports Medicine interviewed him about his journey in this arena and next steps.

M3 - Other contribution

VL - 3

PB - CELL PRESS

ER -

Q&A John Maher

Abstract

Access to Document

Fingerprint

Cite this